Goldman Sachs Added Novartis AG (NVS) To Buy List, GlaxoSmithKline (GSK) To Sell List
More News related to GSK
- Human Genome (HGSI) Raises Money As It Gears Up for Benlysta Approval
- Gilead Sciences (GILD) and Glaxo (GSK) Agree to Commercialize Viread Hep B Treatment in Five Asian Countries
- Gilead and GlaxoSmithKline Announce Agreement to Commercialize Viread(R) for Chronic Hepatitis B in Key Asian Countries
- Leerink Swann Initiates Coverage on GlaxoSmithKline (GSK) with a Market Perform
- Valent Pharma (VRX) Shares Ride the Lightning, But Is the Storm Breaking? - Barron's (GSK)
More News related to NVS
- Despite Novartis Denial, UBS Makes A Strong Case That They Should Buy Alcon (ACL)
- Novartis (NVS) has no plans to buy out Alcon (ACL) minority shares - Bloomberg
- Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting
- Vanda Pharma (VNDA) to Receive $200M from Novartis (NVS) Upon Expiration of HSR Antitrust Improvements Act
- FDA Approves Agriflu Seasonal Influenza Vaccine
More News related to Analyst Comments
- Cramer Tries His Best to Top-Tick Amazon (AMZN), Sets Street High $210 Price Target
- Despite Novartis Denial, UBS Makes A Strong Case That They Should Buy Alcon (ACL)
- JPMorgan (JPM) Could See $3B Revenues Hit On Derivatives Rules
- Goldman Issues 'Top Trades of 2010': Sees 2010, 2011 'Rather Strong Years', Gives Global, US, Euro, BRIC GDP Estimates
- More Thoughts On Apple's (AAPL) Quick Sell-Off Yesterday
Goldman Sachs added Novartis AG (NYSE: NVS) to its Conviction Buy List and added GlaxoSmithKline plc (NYSE: GSK) to its Conviction Sell List.
Related Categories
Analyst CommentsStocks Mentioned
-0.03Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
